BriaCell Therapeutics Corp. SEC filings BCTXL
BriaCell Therapeutics Corp. has 324 filings in SEC EDGAR's recent list, going back to Jun 20, 2014. Its latest annual report, Form 10-K, was filed on Oct 28, 2026 for the period ended Jul 31, 2026. The latest quarterly report (Form 10-Q) was filed on Jun 9, 2026, covering the quarter ended Apr 30, 2026. The most recent current report (Form 8-K) was filed on Jun 26, 2026 (regulation fd disclosure). The company's fiscal year ends on July 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 424B5 | Prospectus supplement | Jun 2, 2026 | — |
| 424B4 | Prospectus | Jan 14, 2026 | — |
| S-1MEF | Filing | Jan 13, 2026 | — |
| FWP | Free writing prospectus | Dec 23, 2025 | — |
| S-1 | Registration statement | Dec 23, 2025 | — |
| S-8 | Employee stock plan registration | Aug 1, 2025 | — |
| 424B4 | Prospectus | Jul 16, 2025 | — |
| FWP | Free writing prospectus | Jul 11, 2025 | — |
| S-1/A | Amended registration statement | Jul 10, 2025 | — |
| S-1/A | Amended registration statement | Jul 9, 2025 | — |
| FWP | Free writing prospectus | Jul 8, 2025 | — |
| S-1 | Registration statement | Jul 8, 2025 | — |
| 424B4 | Prospectus | Apr 28, 2025 | — |
| 424B4 | Prospectus | Apr 28, 2025 | — |
| S-1MEF | Filing | Apr 24, 2025 | — |
| S-1/A | Amended registration statement | Apr 23, 2025 | — |
| FWP | Free writing prospectus | Apr 22, 2025 | — |
| S-1 | Registration statement | Apr 22, 2025 | — |
| 424B5 | Prospectus supplement | Feb 4, 2025 | — |
| 424B5 | Prospectus supplement | Feb 3, 2025 | — |
| 424B5 | Prospectus supplement | Dec 12, 2024 | — |
| 424B5 | Prospectus supplement | Dec 11, 2024 | — |
| 424B5 | Prospectus supplement | Oct 2, 2024 | — |
| 424B5 | Prospectus supplement | Sep 12, 2024 | — |
| 424B5 | Prospectus supplement | May 16, 2024 | — |
| S-3 | Shelf registration | Jan 22, 2024 | — |
| POS AM | Filing | Mar 20, 2023 | — |
| 424B3 | Prospectus | Mar 21, 2022 | — |
| POS AM | Filing | Mar 10, 2022 | — |
| 424B3 | Prospectus | Nov 26, 2021 | — |
| POS AM | Filing | Nov 19, 2021 | — |
| 424B3 | Prospectus | Oct 18, 2021 | — |
| 424B3 | Prospectus | Jun 25, 2021 | — |
| F-1 | Registration statement (foreign issuer) | Jun 15, 2021 | — |
| 424B4 | Prospectus | Feb 26, 2021 | — |
| 424B4 | Prospectus | Feb 25, 2021 | — |
| F-1/A | Filing | Feb 18, 2021 | — |
| F-1/A | Filing | Feb 3, 2021 | — |
| F-1/A | Filing | Jan 15, 2021 | — |
| F-1/A | Filing | Dec 23, 2020 | — |
| F-1/A | Filing | Dec 10, 2020 | — |
| F-1/A | Filing | Oct 20, 2020 | — |
| F-1/A | Filing | Sep 18, 2020 | — |
| F-1/A | Filing | May 27, 2020 | — |
| F-1/A | Filing | May 18, 2020 | — |
| F-1/A | Filing | Mar 13, 2020 | — |
| F-1/A | Filing | Feb 21, 2020 | — |
| F-1/A | Filing | Jan 23, 2020 | — |
| F-1/A | Filing | Jan 21, 2020 | — |
| F-1/A | Filing | Nov 27, 2019 | — |
| F-1/A | Filing | Nov 12, 2019 | — |
| F-1 | Registration statement (foreign issuer) | Oct 22, 2019 | — |
Showing 52 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- BCTX (Nasdaq), BCTXL (Nasdaq), BCTXZ (Nasdaq)
- Fiscal year ends
- July 31
- Incorporated in
- British Columbia, Canada
- Headquarters
- West Vancouver, British Columbia, Canada
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1610820
- Former names
- Ansell Capital Corp. (until Jun 20, 2014)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.